Risk-enhancing factors and social determinants of health in risk assessment for atherosclerotic cardiovascular disease.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 01 04 2024
accepted: 11 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

The Pooled Cohort Equations (PCEs) do not accurately estimate atherosclerotic cardiovascular disease (ASCVD) risk in certain populations. The 2018 AHA/ACC cholesterol guideline identified risk-enhancing factors as a supplement to PCEs-based risk assessment. However, the role of each risk-enhancing factor in ASCVD risk assessment has not been well quantified. Further, social determinants of health (SDOH) are not included in the PCEs nor considered as risk-enhancing factors in the US cholesterol guideline. We sought to evaluate ASCVD risk associated with each risk-enhancing factor and commonly collected SDOH including education, income, and employment status, and to assess if adding risk-enhancing factors and SDOH to the PCEs improve ASCVD risk prediction. We included individuals aged 40 to 75 years, without ASCVD or diabetes at baseline, and with low-density lipoprotein cholesterol 70-189 mg/dL from two contemporary prospective cohort studies (MESA and REGARDS) and from Kaiser Permanente Southern California (KPSC). The primary endpoint was incident ASCVD defined as nonfatal myocardial infarction, fatal coronary heart disease, or fatal or nonfatal stroke over a 10-year period (median follow-up 10 years). We used Cox proportional hazards models to estimate associations between risk-enhancing factors and SDOH with ASCVD. We also assessed changes in model performance after adding risk-enhancing factors and SDOH to the PCEs. We included 13,863 adults (mean age 60.7 years) from the prospective cohorts and 307,931 adults (mean age 54.8 years) from KPSC. Risk-enhancing factors including hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, and chronic kidney disease were associated with a higher ASCVD risk, independent of 10-year risk estimated by the PCEs. Low education, low income, and unemployment were also associated with higher ASCVD risk. While adding individual risk-enhancing factors or SDOH to the PCEs had limited impact on model performance, adding multiple risk-enhancing factors and SDOH simultaneously led to modest improvements in discrimination (C-index increased by up to 0.07), calibration (integrated Brier score reduced by up to 2.3%), and net reclassification improvement up to 41.4%. These findings suggest including SDOH and risk-enhancing factors may improve ASCVD risk assessment.

Sections du résumé

BACKGROUND BACKGROUND
The Pooled Cohort Equations (PCEs) do not accurately estimate atherosclerotic cardiovascular disease (ASCVD) risk in certain populations. The 2018 AHA/ACC cholesterol guideline identified risk-enhancing factors as a supplement to PCEs-based risk assessment. However, the role of each risk-enhancing factor in ASCVD risk assessment has not been well quantified. Further, social determinants of health (SDOH) are not included in the PCEs nor considered as risk-enhancing factors in the US cholesterol guideline. We sought to evaluate ASCVD risk associated with each risk-enhancing factor and commonly collected SDOH including education, income, and employment status, and to assess if adding risk-enhancing factors and SDOH to the PCEs improve ASCVD risk prediction.
METHODS METHODS
We included individuals aged 40 to 75 years, without ASCVD or diabetes at baseline, and with low-density lipoprotein cholesterol 70-189 mg/dL from two contemporary prospective cohort studies (MESA and REGARDS) and from Kaiser Permanente Southern California (KPSC). The primary endpoint was incident ASCVD defined as nonfatal myocardial infarction, fatal coronary heart disease, or fatal or nonfatal stroke over a 10-year period (median follow-up 10 years). We used Cox proportional hazards models to estimate associations between risk-enhancing factors and SDOH with ASCVD. We also assessed changes in model performance after adding risk-enhancing factors and SDOH to the PCEs.
RESULTS RESULTS
We included 13,863 adults (mean age 60.7 years) from the prospective cohorts and 307,931 adults (mean age 54.8 years) from KPSC. Risk-enhancing factors including hypercholesterolemia, hypertriglyceridemia, metabolic syndrome, and chronic kidney disease were associated with a higher ASCVD risk, independent of 10-year risk estimated by the PCEs. Low education, low income, and unemployment were also associated with higher ASCVD risk. While adding individual risk-enhancing factors or SDOH to the PCEs had limited impact on model performance, adding multiple risk-enhancing factors and SDOH simultaneously led to modest improvements in discrimination (C-index increased by up to 0.07), calibration (integrated Brier score reduced by up to 2.3%), and net reclassification improvement up to 41.4%.
CONCLUSIONS CONCLUSIONS
These findings suggest including SDOH and risk-enhancing factors may improve ASCVD risk assessment.

Identifiants

pubmed: 39453943
doi: 10.1371/journal.pone.0312756
pii: PONE-D-24-12776
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0312756

Informations de copyright

Copyright: © 2024 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: LDC receives research support from Amgen, unrelated to this work.

Auteurs

Yiyi Zhang (Y)

Division of General Medicine, Columbia University Irving Medical Center, New York, NY, United States of America.

Jaejin An (J)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States of America.

Mengying Xia (M)

Division of General Medicine, Columbia University Irving Medical Center, New York, NY, United States of America.

Hui Zhou (H)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States of America.

Yifei Sun (Y)

Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, United States of America.

Joanie Chung (J)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.

Mengnan Zhou (M)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.

Soon Kyu Choi (SK)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.

Kerresa L Morrissette (KL)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.

Paul Muntner (P)

Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States of America.

Monika M Safford (MM)

Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, NY, United States of America.

Carmen R Isasi (CR)

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States of America.

Alka M Kanaya (AM)

Department of Medicine, University of California San Francisco, San Francisco, CA, United States of America.

Brandon K Bellows (BK)

Division of General Medicine, Columbia University Irving Medical Center, New York, NY, United States of America.

Lisandro D Colantonio (LD)

Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, United States of America.

Kristi Reynolds (K)

Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States of America.

Andrew E Moran (AE)

Division of General Medicine, Columbia University Irving Medical Center, New York, NY, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH